Erasca Financial Statements
NASDAQ: ERASHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.03+0.57 (+3.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Erasca revenue and earnings
Erasca reported a net loss of $124.5 million, compared with a loss of $161.7 million a year earlier. Diluted earnings per share came in at -$0.44.
Summary generated from market data by MetaCap's automated system. Methodology
Erasca income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | 140.91M | 179.59M | 141.53M | 247.45M | 124.88M | 109.25M |
| Research & Development | 92.85M | 115.36M | 103.82M | 112.46M | 73.92M | 29.55M |
| Operating Income | -140.91M | -179.59M | -141.53M | -247.45M | -124.88M | -109.25M |
| Other Income (Expense) | 16.36M | 17.94M | 16.48M | 4.64M | 2.12M | 7.59M |
| Pretax Income | -124.55M | -161.65M | — | — | — | — |
| Income Tax | 0 | 0 | — | — | — | — |
| Net Income | -124.55M | -161.65M | -125.04M | -242.81M | -122.76M | -101.66M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 | -4.83 |
| EPS (Diluted) | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 | -4.83 |
| Shares Outstanding (Basic) | 283.53M | 233.82M | 150.18M | 122.02M | 66.29M | 21.04M |
| Shares Outstanding (Diluted) | 283.53M | 233.82M | 150.18M | 122.02M | 66.29M | 21.04M |
| EBITDA | -137.80M | -175.78M | -137.79M | -244.81M | -124.05M | -108.71M |
This table shows 6 annual periods of Erasca's income statement, from FY 2025 back to FY 2020, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow ERAS's reporting calendar. What is a income statement?